Price Chart

Profile

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
URL https://www.molecularpartners.com
Investor Relations URL https://investors.molecularpartners.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 14, 2025 (est.)
Last Earnings Release Aug. 26, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
URL https://www.molecularpartners.com
Investor Relations URL https://investors.molecularpartners.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 14, 2025 (est.)
Last Earnings Release Aug. 26, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A